Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07034768 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate EDG-7500 in People With Renal Impairment
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT07034768 is a Phase 1 study that has completed, run by Edgewise Therapeutics. The registered enrollment target is 37 participants.
The verdict
NCT07034768, a Phase 1 study, has completed, sponsored by Edgewise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.
Interventions
- DRUG EDG-7500
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2025-07-22 |
| Est. Completion | 2025-12-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07034768
The ClinicalTrials.gov registry entry for NCT07034768 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EDG-7500 is the first listed.
NCT07034768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07034768 about?
NCT07034768 is a clinical study titled "A Study to Evaluate EDG-7500 in People With Renal Impairment". The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of ...
What is the current status of trial NCT07034768?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2025-07-22. Estimated completion is 2025-12-26.
What interventions are being tested in trial NCT07034768?
The interventions under investigation include: EDG-7500 (DRUG).
Who is sponsoring clinical trial NCT07034768?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.